ViroMed to Present at Biotech Japan 2017 Keynote Session
VM202’s Potential to Become First
in class & Best in class in Advanced Markets
is presenting novel drug development cases, including the results from its
clinical trials of VM202-DPN and VM202-PAD, at a Keynote session of one of the
biggest and most comprehensive biopharma events in Asia, Biotech Japan 2017 taking place on Jun 28-30 at the Tokyo Big Sight.
is an innovative medicine under development targeting diabetic peripheral neuropathy
(DPN) and diabetic/ischemic chronic non-healing foot ulcer (NHU), whose phase
III clinical trials are underway in the US. Basically, VM202 is plasmid DNA
containing hepatocyte growth factor (HGF), which can be delivered through
intramuscular injection to induce formation of new blood vessels and
regeneration of damaged nerve cells.
the only plasmid DNA undergoing phase III clinical trial targeting DPN in the
US, its safety and efficacy profile as well as neuroregenerative potential have
been confirmed through the phase I and phase II trials. VM202 has been shown to
downregulate the expression levels of pain related genes in the spinal cord and
the dorsal root ganglion (DRG) as well as to induce remyelination, whose
mechanism demonstrates a potential to become Disease Modifying Drug, a drug that
treats not only symptoms but also fundamental causes.
research of plasmid DNA using an angiogenic growth factor has been carried out
since the late 1990s. AnGes MG, a Japanese company, has recently announced that
it would apply for an approval on HGF plasmid (Beperminogene perplasmid) in the
Japanese market targeting critical limb ischemia (CLI), signaling
commercialization of plasmid DNA medicine.
successfully completed phase I and phase II clinical trials of VM202 targeting
CLI in the US, and its ongoing phase III is targeting chronic non-healing ulcer
(NHU), which is a pre-stage condition before CLI and has about 3-4 times more
patients globally than CLI, securing market opportunity that is more expandable
than that of AnGes MG.
the excellence of substance, its developmental status, and the size of
potential market as well as its expandability, VM202 is well expected to become
a First-in-Class and Best-in-Class medicine in advanced markets.
addition to its research on gene therapy, ViroMed is presenting the results of its
research and development on phytotherapeutics while participating in the
start-up poster booths to promote its phytotherapeutic products.
Biotech Japan 2017
One of the biggest and most comprehensive biopharma
events in Asia held at the Tokyo Big Sight on Jun 28-30.
ViroMed will be part of,
- Dr. Sunyoung Kim, CSO, Guest speaker
- Subject: Development of Innovative Drugs Using Plasmid DNA
Case of Diabetic Peripheral Neuropathy (DPN)
- Date: Jun 28, 12:30 - 14:30
presentation / Phytotherapeutics research: Jun 28, 15:50 - 16:20
(3) Exhibition booth /
Start-up poster: Jun 28-30 (3 days)